Pricing Log in Create free account
Saturday 17 October 2026 Export LLY’s income statement to Excel — free account

Eli Lilly and Company

LLY Healthcare Drug Manufacturers General

Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 26.2%, free cash flow grew 458.1% and total debt rose 37.6%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years, revenue growth for five.

1,257.03 5.42 +0.43%
Market cap
$1.18T
P/E
42.2×
Fwd P/E
33.1×
Dividend yield
0.53%
F-score
7/9
Altman Z
8.61
Beneish M
−1.91
Dividend safety
86/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Eli Lilly and Company (LLY) EV/Sales

Alert me on EV/Sales

As of 16 October 2026, Eli Lilly and Company (LLY) trades at a EV/Sales of 14.7×. Over the past ten years it has ranged from 3.6× (December 2016) to 23.5× (June 2024); the current reading is higher than 81% of that period. That is above the Drug Manufacturers General industry median of 4.0× and above the Healthcare sector median of 3.4×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 15.3× (4.28%)
FY2024 16.0× (0.73%)
FY2023 16.1× 34.24%
FY2022 12.0× 29.21%
FY2021 9.3× 37.42%
FY2020 6.8× 11.64%
FY2019 6.1× 7.98%
FY2018 5.6× 23.28%
FY2017 4.6× 18.94%
FY2016 3.8× (17.80%)

Quarterly newest first

Period EV/Sales Change
Jun 2026 14.0× 17.93%
Mar 2026 11.9× (22.52%)
Dec 2025 15.3× 26.38%
Sep 2025 12.1× (12.23%)
42 more quarters

Against its own ten years

Low 3.6× High 23.5×
Ten-year median 7.0×
Current reading's percentile 80

EV/Sales against peers

Company EV/Sales
PFE Pfizer Inc. compare 3.5×
AZN AstraZeneca PLC compare 4.6×
NVS Novartis AG compare 5.8×
MRK Merck & Co., Inc. compare 6.1×
JNJ Johnson & Johnson compare 6.4×
GILD Gilead Sciences, Inc. compare 7.1×
AMGN Amgen Inc. compare 7.3×
ABBV AbbVie Inc. compare 8.8×
LLY Eli Lilly and Company 14.7×
Drug Manufacturers General industry median 4.0×
Healthcare sector median 3.4×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on LLY